Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 35,419 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Soft Tissue Sarcoma
Interventions: Dendritic Cell (DC) Injections, Radiation therapy, Complete Resection - Surgery for tumor removal; Biological · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Gastroesophageal Reflux Disease
Interventions: Web-based CBTI; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Myeloid Leukemia
Interventions: Decitabine and Cedazuridine, Enasidenib, Gilteritinib, Ivosidenib, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Texting; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 15 Years to 21 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy
Interventions: ILV-094; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: Ravulizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Knee Osteoarthritis
Interventions: Amniotic Suspension Allograft, Placebo; Biological · Drug
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 38
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 30 more

Conditions: Healthy
Interventions: NRX-1074, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Disruptive Behavior, Attention-deficit Hyperactivity, Oppositional Defiant Disorder
Interventions: Garmin; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection
Interventions: V4020; Biological
Lead sponsor: Medigen, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dental Phobia, Dental Anxiety in Children, Dental Fear, Dental Fear and Anxiety
Interventions: One-Session Treatment for Dental Phobia (OSTD), Psychoeducation and Relaxation Training (RELAX); Behavioral
Lead sponsor: University of Texas Rio Grande Valley; Other
Eligibility: 7 Years to 16 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Brownsville, Texas • Edinburg, Texas

Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Pancreas Cancer
Interventions: Immunotherapy, Chemotherapy, CRC surgical resection, Colonoscopy; Drug · Procedure
Lead sponsor: Persephone Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: Orange, California • San Diego, California • Miami, Florida + 6 more

Conditions: Locally Advanced Solid Tumor
Interventions: TNG462, Pembrolizumab; Drug
Lead sponsor: Tango Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Palo Alto, California • Grand Junction, Colorado • Lake Mary, Florida + 11 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
Interventions: AEG35156 antisense IV infusion; Drug
Lead sponsor: Aegera Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Burbank, California • Valhalla, New York • Cleveland, Ohio + 1 more

Conditions: Tumors
Interventions: Fosbretabulin, Carboplatin, Paclitaxel, Bevacizumab; Drug
Lead sponsor: Mateon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 15
States / cities: Campbell, California • Fountain Valley, California • Los Angeles, California + 12 more

Conditions: Tonsillectomy, Infections
Interventions: Full-Body Surgical Draping, Head-Only Surgical Draping; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis
Interventions: Canakinumab, Placebo to canakinumab, Naproxen, Placebo to Naproxen; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Anniston, Alabama • Mesa, Arizona • San Diego, California + 5 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more

Conditions: Breast Cancer
Interventions: Blood draw, immunoenzyme technique, biopsy, histopathologic examination; Other · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Freeman-Burian Syndrome, Freeman-Sheldon Syndrome, Whistling Face Syndrome, Sheldon-Hall Syndrome, Freeman-Sheldon Syndrome Variant, Arthrogryposis Distal Type 1, Arthrogryposis Distal Type 3, Gordon Syndrome
Interventions: Guided Health History for Freeman-Burian Syndrome Questionnaire, Freeman-Burian syndrome Semi-Structured Quality of Life Interview, Medical Records Review, PTSD Checklist for DSM-5, Modified Flanagan Quality of Life Scale, Center for Epidemiologic Studies Depression Scale, Review of Systems, FACE-Q | Craniofacial - Appearance of the Face, FACE-Q | Craniofacial - Appearance Distress, FACE-Q | Craniofacial - Facial Function; Other
Lead sponsor: Dufresne, Craig, MD, PC; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Chronic Anovulation
Interventions: Additional office hysteroscopy, Endometrial biopsy; Procedure
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Posttraumatic Stress Disorder
Interventions: Attentional bias retraining; Behavioral
Lead sponsor: VA Pacific Islands Health Care System; Federal
Eligibility: 18 Years to 89 Years · Male only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Hyperalgesia, Allodynia
Interventions: Fenobam, Placebo; Drug
Lead sponsor: Laura Cavallone; Other
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma

Cognitive Behavioral Therapy for Insomnia (CBTI) in GERD Patients With Insomnia

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Adolescent Self-Care and Knowledge Education in Diabetes--Improved by Texting

Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers

Monitoring of Sleep and Behavior of Children 3-7 Years Old Receiving Parent-Child Interaction Therapy With the Help of Artificial Intelligence

A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers

Study of Anxiety Free Experiences at the Dentist

ARGONAUT: Stool and Blood Sample Bank for Cancer Patients

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Triple Therapy in T1DM

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

Head-Only Draping in Pediatric Tonsillectomy

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer

Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome

Hysteroscopy in Chronic Anovulation

Attentional Bias Retraining in Veterans

Fenobam on Heat/Capsaicin Induced Hyperalgesia in Healthy Volunteers